CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79.75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Astellas Signs Option and License Deal With Audax for Cancer Drug Worth Up to US$ 1.34 Billion

By Public Technologies
  • Astellas Pharma entered an exclusive option agreement with Audax Biosciences for worldwide rights to develop, manufacture and commercialize cancer drug DAX-044.
  • The deal totals up to US$1.34 billion excluding royalties, including US$285 million in upfront and potential option exercise payments.
  • Audax could receive up to US$1.05 billion in development and commercial milestones, alongside tiered double-digit royalties on worldwide net sales if approved.
  • Audax will fund development into Phase 1, expected to begin in 2027; exercising the option transfers global responsibility to its partner.
  • The agreement gives Audax the option to co-fund and co-promote DAX-044 in Australia and New Zealand.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astellas Pharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610271930PR_NEWS_USPR_____CG80688) on October 27, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.